The World Health Organization warned that artificial sweeteners, used to replace sugar in a vast range of products, do not help in losing weight and can have serious health effects.
According to the United Nations health agency, a systematic review of available evidence "suggests that use of non-sugar sweeteners (NSS) does not confer any long-term benefit in reducing body fat in adults or children.
In addition, results from the review suggest that the long-term use of NSS could increase the risk of type 2 diabetes, cardiovascular diseases, and mortality in adults.
The WHO's director for nutrition and food safety, Francesco Branca, stressed that replacing ordinary sugar with artificial sweeteners "does not help with weight control in the long term".
He added that NSS are not essential dietary factors and have no nutritional value.
The WHO said its new recommendation applied to everyone except individuals with pre-existing diabetes.
It includes all synthetic and naturally occurring or modified sweeteners not classified as sugars found in manufactured foods and beverages or sold on their own to be added to products by consumers.
Among the most widely used sweeteners are acesulfame K, aspartame, advantame, cyclamates, neotame, saccharin, sucralose, stevia, and stevia derivatives, it said.


China Shuts 670 Banks as Bitcoin Eyes Financial Risks
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss
Trump Signs Order to Cut Routine Childhood Vaccines
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds
SpaceX Seeks $40 Billion for Nvidia AI Chips
Intel Reaffirms Role in Elon Musk’s Terafab Chip Project
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
U.S. Issues Cuba Health Alert as Illnesses Rise
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
Ripple Expands Brevan Howard Deal With Prime Brokerage Services
FDA Weighs Safety Standards for Psychedelic Therapies
Gold Prices Slip as Strong Dollar and High Treasury Yields Weigh
Zcash Prepares for NU7 Upgrade as Zebra Gets Key Security Fixes
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
JPMorgan CEO Jamie Dimon Warns Mythos AI Raises Cyber Risk Tenfold
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 



